Karuna Three-For-Three As Another KarXT Schizophrenia Trial Hits Primary Endpoint

The company is on track for a mid-2023 FDA filing, while executives suggested that they would likely pursue partnership for commercialization of the drug in Europe.

Karuna announced results of a third positive study of KarXT in schizophrenia • Source: Shutterstock

Karuna Therapeutics, Inc. has posted positive results from a third clinical trial of KarXT (xanomeline-trospium) in adults with schizophrenia with the announcement that the Phase III EMERGENT-3 trial met its primary endpoint of showing a meaningful reduction in the Positive and Negative Syndrome Scale (PANSS) score. The data indicate the drug should see commercial success, with analysts deeming its efficacy comparable to prior antipsychotics but with a differentiated side effect profile.

Karuna announced the results on 20 March, making EMERGENT-3 the third trial in the EMERGENT program and the second in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Kailera Eyes Global Obesity Market With Hengrui’s Phase III Dual Agonist

 
• By 

With China’s Hengrui reporting successful Phase III data for its dual GLP-1/GIP agonist, licensee Kailera is readying plans to demonstrate better efficacy than current obesity drugs.

Sellas Targets Tambiciclib To Adverse-Risk Frontline AML Patients After Phase II Success

 

The biotech announced positive Phase II data for the drug combined with AbbVie/Roche’s Venclexta and BMS’s Vidaza in relapsed/refractory acute myeloid leukemia.

Takeda Prepares Ground For Oveporexton In Narcolepsy

 

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Leo Lands Another Big Pharma Pact With Boehringer Spevigo Deal

 
• By 

Paying €90m upfront for rights to generalized pustular psoriasis drug.

More from R&D

Bayer’s Kerendia Gains Blockbuster Indication For Heart Failure

 
• By 

New US approval in heart failure with preserved or mildly reduced ejection fraction should add to Kerendia’s earning power on top of chronic kidney disease indication.

Takeda Prepares Ground For Oveporexton In Narcolepsy

 

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Phase III Success For AstraZeneca’s $5bn Hypertension Hope Baxdrostat

 

Rivals Mineralys could be first to file but AstraZeneca is banking on its cardiovascular market know-how to lead the emerging class.